hotspot -WSS

hotspot

author：comprehensive 2025-10-01 22:48:58 - browse：655

3d rendered medically accurate illustration of the adrenal gland – biotech and pharma coverage from STAT — Adobe

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones.

In the Phase 3 study, known as CAHtalyst, 182 adults were randomly assigned to receive a placebo or crinecerfont, an oral drug Neurocrine developed to lower male sex hormones patients with the disease produce in excess. Researchers found that, compared to those on placebo, participants who took crinecerfont needed a significantly lower dose of the current standard-of-care treatment, glucocorticoids, after 24 weeks of treatment that they did at the study’s start. And about 63% of participants who took crinecerfont were able to lower their dose of glucocorticoids to levels researchers think would be safer for prolonged use, compared to 18% of those on the placebo.

Neurocine, a San Diego biotech focused on treating rare neurological and endocrine diseases, believes the drug could allow people living with congenital adrenal hyperplasia, or CAH, to avoid some of the more serious side effects of glucocorticoids by allowing them to take lower doses. Long-term use of high doses of these drugs can cause patients to gain weight and put them at risk of diabetes, heart disease, and osteoporosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Medicare details structure of new drug price negotiation program

WSS

Supreme Court strikes down use of affirmative action

Medicare proposal to cover medical devices draws a mixed reaction

Supreme Court strikes down use of affirmative action

Walensky prepares to leave CDC — and Congress — behind

Trump demands the U.S. pay no more for drugs than other countries … again

FDA approves Sage Therapeutics’ rapid

leisure time

hotspot

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Group behind ProMed defends move to subscription

In age of alternative facts, a scholarly course on calling out crap

Heart attack and stroke risk calculators need revising

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Medicare slashes safety net hospital payments by nearly $1 billion

Walensky prepares to leave CDC — and Congress — behind

At least 13 dead in Texas as scorching temps continue

What does generative AI mean for health care? We asked experts

Guidelines to prevent youth baseball injuries need more muscle

knowledge

The high cost of giving birth even with insurance

BioMarin wins approval for gene therapy to treat hemophilia A

Pharma showers House GOP doctor with campaign cash

Chris Christie meets with Zelenskyy during Ukraine trip

New air purifier tech could be key to improving indoor air quality

FDA scientists endorse Pfizer/BioNTech Covid

knowledge

explore

Wikipedia

hotspot